Methods for determining the risk of cardiovascular disease in a subject having a chronic viral infection through the measurement of lysophosphatidic acid
AssigneeCase Western Reserve University
InventorMark R. Chance
Life of this patent
Estimating the term…
Abstract
A method for determining the risk of cardiovascular disease in a subject having a chronic viral infection includes determining a level of determining a level of at least one lysophophatidic acid (LPA) subtype in the subject, wherein the LPA subtype is selected from the group consisting of LPA 16:0, 18:1, 18:2, and 20:4 and comparing the determined level of the at least one LPA to a control level, wherein an increased level of at least one LPA subtype is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection.
Claims32
A method of determining the risk of cardiovascular disease in a subject having a chronic viral infection, the method comprising:
- determining the level of one or more lysophosphatidic acid (LPA) subtypes in the subject, wherein the one or more LPA subtypes are selected from the group consisting of LPA 16:0, 18:1, 18:2, and 20:4;
- comparing the determined level of the one or more LPA subtypes to a control level, wherein an increased level of the one or more LPA subtypes is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection;
- and
- administering a therapeutically effective amount of an ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase-2) inhibitor to the subject if the subject has an increased risk of cardiovascular disease associated with the chronic viral infection.
A method for treating cardiovascular disease associated with chronic viral infection in a subject, the method comprising the steps of:
- determining the level of one or more lysophosphatidic acid (LPA) subtypes in the subject, wherein the one or more LPA subtypes are selected from the group consisting of LPA 16:0, 18:1, 18:2, and 20:4 and
- administering a therapeutically effective amount of an ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase-2) inhibitor to the subject if the determined level of one or more LPA subtypes is increased relative to a control level.
Dependencies are inferred from the claim text.